ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
← catalyst calendarNCT04587830 · readout in 193 d
Sponsored by Polaris Group (industry) · PII — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100actual
Sites
10
Countries
South Korea, Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-14 | actual | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma Multiforme (GBM)
Interventions
- Drug: ADI-PEG 20
- Drug: Temozolomide
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS)
measured Through study completion, 2.5 year anticipated
Permalink · PII's whole pipeline · Catalyst calendar · Every registered study · What changed